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Background: The incidence, prevalence, and even the clinical
behavior of ulcerative colitis (UC) are highly variable in differ-
ent world regions. In previous studies, Portugal was reported as
having a milder clinical behavior. The aim of this study was
to apply the Montreal Classiﬁcation in a large group of UC
Portuguese patients in order to describe their clinical character-
istics and evaluate variables potentially useful for outcome
prediction.
Methods: A cross-sectional study based on data collected from
a nationwide online registry was undertaken.
Results: In all, 2863 patients with UC were included. Twenty-
one percent had ulcerative proctitis, 52% left-sided colitis, and
28% extensive colitis. Sixty percent of patients had taken steroids,
14% immunosuppressors, 1% biologicals, and 4.5% were submit-
ted to surgery. Patients with extensive colitis had more severe ac-
tivity, needing more steroids, immunosuppressors, and surgery. At
the time of diagnosis 61% were less than 40 years old and 5%
less than 16. Younger patients also had a more aggressive initial
course. Thirty-eight percent of patients had only taken salicylates
during the disease course and were characterized by a lower inci-
dence of systemic symptoms at presentation (3.8% versus 8.8%,
P < 0.001), fewer extraintestinal manifestations (7.7% versus
24.0%, P < 0.001), and a higher prevalence of proctitis (32.1%
versus 10.0%).
Conclusions: A more aggressive phenotype was found in exten-
sive colitis and in the initial course of younger patients, with an
increased need for steroids and immunosuppressors. In addition, a
signiﬁcant percentage of patients, particularly with proctitis,
showed a milder clinical evolution and were maintained in remis-
sion only with salicylates.
(Inﬂamm Bowel Dis 2009;16:822–829)
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T he incidence and prevalence of ulcerative colitis (UC)varies widely in different countries and from time to
time. In Shivananda et al’s1 European study a north–south
gradient was apparent (rates in northern centers were 40%
higher than those in the south), although with less than that
previously reported. Concerning the years 1991–1993, the
lowest UC incidence was found in Portugal (1.6/105 in
Almada, south of Portugal), but recent data suggest an
increase in these numbers following a similar trend in other
southern European countries.2 The prevalence of UC in
Portugal was estimated at 61.8 per 1053 in 2007 and is mid-
level between countries with the highest prevalence estimates
and those with the lowest, but apparently heading toward the
highest level group. Along with a low incidence, there were
also previous data pointing to a milder clinical activity4 in
comparison with other European countries, but there is a
lack of recent local studies conﬁrming this scenario.
Herein, a national cross-sectional study was carried
out with patients from most of the hospitals and clinics
serving UC patients all over the country. The Montreal
Classiﬁcation was applied in an effort to identify different
clinical patterns in terms of medical and surgical needs. To
our knowledge this methodology has never been applied in
such a large nationwide study.
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MATERIALS AND METHODS
During a 15-month period (September 2005 to De-
cember 2006), Portuguese doctors following patients with
inﬂammatory bowel disease (IBD) had the opportunity to
collect general characteristics and clinical data and upload
this information to a central database using an online regis-
try (http://www.gedi.med.up.pt/). Patient registration was
carried out through a Web-based system with password and
user name validated by a scientiﬁc committee. The data-
base was approved by national authorities and was sup-
ported by the Portuguese IBD Study Group (Grupo de
Estudos da Doenc¸a Inﬂamato´ria Intestinal–GEDII). Seventy
doctors from 33 hospitals and small clinics participated in
the study. The information was collected from clinical
charts during a routine medical examination that was also
used to complete the data collection. Several meetings
were organized before and during the inclusion period to
standardize and clarify the different criteria and parameters
to be used and collected.
The diagnostic criteria for UC were based on a sug-
gestive clinical history, associated with endoscopic and his-
tological signs of inﬂammation of the mucosa, and infec-
tious disease excluded by culture and microscopic stool
examination.5
For each patient several parameters were collected:
date of symptoms onset and diagnosis, type of clinical
onset, extent of disease, familial occurrence of IBD, extra-
intestinal manifestations, duration of involvement, clinical
course, use and response to steroids, immunosuppression,
biologic treatment, and abdominal and anal surgery. Fever
(37.5C), anemia (Hb  11.5 g/dL), and weight loss
(5%) were considered constitutional symptoms and only
patients submitted to colectomy or proctocolectomy were
considered as being submitted to abdominal surgery. For
the extent of the lesions, the most proximal level (eval-
uated by colonoscopy), achieved at any time since the di-
agnosis, was measured and patients were grouped as having
proctitis, left-sided, and extensive colitis.6 The clinical
course was standardized in three different curves, the ﬁrst
reﬂecting a disease without relapses after the ﬁrst episode
(remission), the second illustrating a disease with chronic
relapsing symptoms (chronic intermittent), and the third
with chronic active behavior (chronic continuous). A
relapse was deﬁned as an exacerbation of the symptoms
that required more intensive medical treatment or surgery.
Regarding steroids, only oral or intravenous forms were
taken into consideration and steroid resistance was assumed
when patients had active disease despite prednisolone up to
1 mg/kg/day over a 4-week period. Steroid dependency
was stipulated as the inability to reduce corticosteroids
below the equivalent of 10 mg/day of prednisolone without
recurrent active disease, or the need for a second course of
steroids in a 6-month period.
Disease severity was deﬁned by the type of treatment
administered (adapted from Loftus et al7). Patients were
categorized into 4 different severity grades: group 1 repre-
senting mild disease (patients with no treatment or with
salicylates); group 2 for those with moderate to severe dis-
ease, drug-responsive (patients treated with steroids, with-
out steroid resistance or steroid dependence); group 3 for
severe disease with drug-dependent or drug-refractory
behavior (patients treated with steroids, with steroid resist-
ance or steroid dependence or immunosuppressors/biologi-
cal); and group 4 for patients with medical refractory dis-
ease, submitted to surgery.
Statistics
Patient and disease characteristics, process of care,
interventions, and treatments are presented as absolute fre-
quency (number) and relative frequency (percentage) for
categorical variables, and as mean and standard deviation
(SD) for continuous variables, if a normal distribution is
assumed, or as median and interquartile range (IQR: 25th–
75th percentile), if normality could not be assumed. The
Kolmogorov–Smirnov test was used to test for normality.
When testing hypotheses concerning continuous vari-
ables, parametric tests (Student’s t-test and 1-factor analy-
sis of variance, ANOVA) and nonparametric tests (Mann–
Whitney and Kruskal–Wallis tests) were used accordingly,
taking into account normality assumptions and number of
groups compared. When testing hypothesis related to cate-
gorical variables, chi-square tests and Fisher’s exact tests
were used as appropriate.
Whenever statistical hypothesis testing was used a
signiﬁcance level of a ¼ 5% was considered. Statistical
analysis was performed using the software Statistical Pack-
age for the Social Sciences v. 15.0 for Windows (SPSS,
Chicago, IL).
RESULTS
Demographic Characteristics
Of the 5893 patients with IBD recorded in the data-
base, 2863 had UC. They came from both tertiary and
quaternary hospitals (48.6%), as well as from regional hos-
pitals and private practices (50.7%). A small percentage
(0.5%) was included by pediatricians working in pediatric
centers. Of the 2863 UC patients, 1619 were female
(56.5%) and 1244 male, yielding a male-to-female ratio of
0.8. The female predominance was highest in a younger
onset (40 years, females 60%; >40 years, females 51%,
P < 0.001).
The median age at diagnosis was 37.8  15.4 years.
In most of the patients the diagnosis was done before 40
years of age (61%), in 7% and 5% of patients UC was
diagnosed before 18 and 16 years, respectively (Fig. 1).
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Median disease duration time was 7.8  7.7 years; 41.6%
had 0–4 years after UC onset, 27.1% 5–9 years, 15.7% 10–
14 years, and ﬁnally 15.3% had more than 15 years. The
patient’s main complaints were rectal bleeding, diarrhea,
and abdominal pain, and 7.6% had constitutional symp-
toms. In 15 patients the initial manifestation was
extraintestinal.
Seven percent had family history of IBD, that is, a
ﬁrst-degree or a second-degree relative with IBD, varying
between 5.4% in those diagnosed after 40 years and 8.2%
in those diagnosed before (P < 0.02).
Regarding smoking status, 7.7% were active smokers,
16.3% former smokers, and 76.1% never smoked.
Association Between Age at Diagnosis and
Disease Course
Patients diagnosed before 16 years of age had a more
aggressive phenotype compared to patients diagnosed
between 17 and 40, and to those diagnosed after 40. They
were characterized by a more chronic active course, exten-
sive colitis (52% versus 28% and 24%, P < 0.001), extra-
intestinal manifestations (26% versus 18% and 12%, P <
0.001), need for steroids (69% versus 62% and 57%, P ¼
0.007), and immunosuppressors (25% versus 16% and
10%, P < 0.001). No differences were found regarding sur-
gical requirement.
The mean disease duration at the time of disease his-
tory assessment could be a confounding factor and a longer
follow-up in younger patients could explain some of the
differences; thus, patients with 5 or fewer years and more
than 5 years of disease duration were analyzed separately.
This analysis showed that most of the differences tend
to vanish in patients with more than 5 years of disease
(Table 1).
Extent of Disease
In 21% of patients the colonic involvement was lim-
ited to the rectum (proctitis), in 52% the inﬂammation was
distal to splenic ﬂexure (left-sided colitis), and in 28% the
involvement was proximal to the splenic ﬂexure (extensive
colitis). A similar age at diagnosis was found in these
groups: proctitis (37  14), left-sided colitis (39  16),
and pancolitis (35 16 years). In contrast, they had differ-
ent medical and surgical needs, namely, steroids (30.8/
61.7/82.4%; P < 0.001), immunosuppressors (1.2/12.3/
28%; P < 0.001) and surgery (0.3/2.5/11.2%; P < 0.001).
Furthermore, they also presented a different disease course,
with a higher percentage of patients in remission in procti-
tis than in patients with left-sided colitis (44%) and panco-
litis (36%) (P < 0.001).
Smoking status did not differ between the 3 groups,
with proctitis, left-sided colitis, and pancolitis having
respectively 7.7%, 7.4%, and 8.1% of smokers, and 14.3%,
18.9%, and 13.5% of former smokers.
Medical and Surgical Treatment
Salicylates were used in almost 98% of the patients,
and in a signiﬁcant proportion, 38% were the only drug
used in treatment. Eighty-four percent used these drugs in
maintenance therapy, mainly in oral (47.6%) or in oral plus
topical administration (27.7%).
Moreover, a total of 1700 (60%) had taken steroids
at least once: 398 (14%) immunosuppressors and 38 (1%)
biologic agents. Eighty-seven (5.1%) were considered ste-
roid-resistant and 293 (17.2%) steroid-dependent.
Among patients treated with steroids, 66% were
never considered corticodependent, corticoresistant, were
never treated with an immunosuppressor (even if they did
not fulﬁll criteria for dependency or resistance to steroids),
or submitted to surgery.
The immunosuppressors most used in clinical prac-
tice were azathioprine and 6-mercaptopurine (92% and
3.6% respectively). A small proportion had been treated
with methotrexate or cyclosporine (2.1%).
In all, 125 patients (4.5%) were submitted to surgery,
mostly due to an acute severe ﬂare or chronic relapsing
disease (90.4%). In 9.6% of the cases the motive for colec-
tomy was colorectal cancer/dysplasia. Higher rates of sur-
gery were observed in males (59% versus 43% in nonsurgi-
cal patients, P < 0.001), in those with constitutional
symptoms at diagnosis (17% versus 8%, P ¼ 0.001), and
in extensive colitis patients (69% versus 25%, P < 0.001).
On the other hand, the group of patients treated only
with salicylates (and without surgery) was characterized by
a slightly older age at diagnosis, fewer systemic symptoms
at presentation, a higher prevalence of proctitis, and fewer
extraintestinal manifestations. Due to the large percentage
of patients with less than 5 years of disease duration in this
age group, additional analysis restricted to those with 5 or
more years of disease was performed. In these patients,
31% (486 out of 1553) were treated only with salicylates
and were characterized, as a whole population, by a lower
incidence of systemic symptoms at presentation (3.8% ver-
sus 8.8%, P < 0.001), fewer extraintestinal manifestations
(7.7% versus 24.0%, P < 0.001), and a higher percentage
of proctitis (32.1% versus 10.0%, P < 0.001).
Disease Severity Over Time
The population was stratiﬁed by the number of years
of disease duration and 6 different subgroups were consid-
ered. In total, 281 patients had <1 year, 850 patients with
1–4 years of disease duration, 737 with 5–9 years, 428
with 10–14 years, 183 with 15–19 years, 135 with 20–24
years, and 103 with at least 25 years of disease duration.
Forty-three percent (1172) of the patients did not have
Inﬂamm Bowel Dis  Volume 16, Number 5, May 2010Portela et al
824
relapses after diagnosis (i.e., new symptoms justifying the
need for more intensive medical treatment or surgery) and
were considered in remission, whereas 49.4% had chronic
intermittent symptoms, and 7.4% had a chronic continuous
behavior. These groups (remission, chronic intermittent,
and continuous course) had different demographic and clin-
ical traits, namely, different age at diagnosis, clinical pre-
sentation, and extent of disease (Table 2). Furthermore, as
a reﬂection of their diversity in disease severity, they had
different therapeutic needs, namely, steroids (43/71/92%),
immunosuppressors (3/17/58%), and surgery (2.4/3.2/
24.1%).In addition, time after diagnosis was similar
between the groups (remission 7.3  7.4; chronic intermit-
tent 8.5  8; and chronic continuous 7.6  6.6 years).
Considering the 4 grades of disease severity previ-
ously mentioned, a trend toward an increasing severity was
found among patients with disease duration of 0–10 years,
followed by a steady state (Fig. 2). The percentage of
patients in group 1 (i.e., no treatment or salicylates)
decreased from 51% in those with less than 5 years of dis-
ease duration, to 34% in patients with 5–9 years, and dur-
ing the same period the percentage of patients in groups 2
and 3 increased from 32% to 40% and from 13% to 20%,
respectively.
DISCUSSION
Although this study was mostly hospital-based, it
included several characteristics that reduced the likelihood
of bias associated with a typical tertiary center-referred
population, with a poorer prognosis than that found in pop-
ulation-based studies. Based on salicylate consumption in
FIGURE 1. Age at diagnosis.
TABLE 1. Age at Diagnosis, Demographics, and Clinical Characteristics of UC Patients
Time After Diagnosis
 5 years > 5 years
Age at Diagnosis Age at Diagnosis
 16 17 - 40 > 40
Total P-valuea
 16 17 - 40 > 40
Total P-valuea
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Sex
Male 16 (33) 299 (43) 295 (53) 610 (47) <0.001b 28 (35) 322 (39) 221 (45) 571 (41) 0.066b
Female 33 (67) 397 (57) 261 (47) 691 (53) 53 (65) 501 (61) 273 (55) 827 (59)
Clinical presentation
With constitutional symptoms 9 (18) 46 (7) 46 (8) 101 (8) 0.013b 10 (12) 56 (7) 19 (4) 85 (6) 0.006b
Without constitutional symptoms 40 (82) 634 (93) 501 (92) 1175 (92) 71 (88) 749 (93) 460 (96) 1280 (94)
Extent of disease
Proctitis 6 (12) 185 (27) 124 (22) 315 (24) <0.001b 11 (14) 154 (19) 80 (16) 245 (18) <0.001b
Left-sided colitis 17 (35) 333 (48) 298 (54) 648 (50) 29 (36) 414 (51) 295 (60) 738 (53)
Pancolitis 26 (53) 175 (25) 131 (24) 332 (26) 41 (51) 251 (31) 118 (24) 410 (29)
Extraintestinal manifestations 12 (25) 104 (15) 50 (9) 166 (13) <0.001b 22 (27) 165 (20) 76 (16) 263 (19) 0.016b
Steroid therapy 30 (61) 375 (55) 269 (49) 674 (52) 0.057b 58 (73) 555 (69) 325 (67) 938 (68) 0.437b
Immunosuppression 17 (35) 107 (16) 42 (8) 166 (13) <0.001b 15 (19) 134 (16) 64 (13) 213 (15) 0.192b
Abdominal surgery 2 (4) 20 (3) 13 (2) 35 (3) 0.728b 7 (9) 52 (6) 24 (5) 83 (6) 0.333b
aP-values for the comparison among age strata.
bChi-square test for independence.
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2005 and considering a daily drug intake-deﬁned dose
(DDD) of 2 g/day, half of the UC patients in Portugal were
considered included in this study,3 but more important,
patients were not only recruited from university hospitals
and tertiary hospitals, but also from smaller hospitals and
even from small clinics and private practices.
In this study a slight female preponderance was
detected, which tends to diminish in older patients, where
the ratio between males and females approaches 1. This is
in accordance with other studies1,8 that found a less pro-
nounced peak-age-speciﬁc incidence in men. Moreover, in
pediatric patients a higher male-to-female ratio was not
demonstrated, which seems to be conﬁned to Crohn’s dis-
ease (CD).9
The low rate of family history (7,2%), found in Por-
tuguese patients could reﬂect an increasing incidence of
IBD, among a population not considered at high risk in the
past, but now facing new environmental factors.
The importance of age at disease onset as a factor in
UC is insufﬁciently studied. In CD there is clear evidence
showing that early-onset represents a distinct and more
aggressive phenotype,10 with greater need for surgery;
however, in relation to UC the data are scarce. In this
cross-sectional study, by applying the same stratiﬁcation
for the variable age at disease onset as the Montreal
Classiﬁcation for CD, younger patients seem to have a
more aggressive initial course, with a higher rate of extra-
intestinal manifestations, pancolitis, and the need for ste-
roids and immunomodulators. This pattern is similar to CD
and is in accordance with some publications indicating a
higher rate of relapse in patients diagnosed at earlier
ages.11–13 However, when patients are restricted according
to disease duration, i.e., more than 5 years of follow-up,
the differences tended to disappear and lose statistical sig-
niﬁcance. These data sustain the notion that a young age at
diagnosis in UC does not imply a more severe prognosis
and does not support its immediate inclusion in the UC
classiﬁcation.
Regarding disease extent, the maximum limit and not
extent at diagnosis was chosen because previous studies
showed that the initial extent did not affect the subsequent
activity course. This approach clearly deﬁned 3 different
groups, with proctitis showing a signiﬁcantly less aggres-
sive phenotype. As such, patients were deﬁned according
to medical or surgical needs, or by the percentage of
patients in remission versus patients with a chronic inter-
mittent or continuous behavior. Pancolitis had the most
severe behavior, and distal colitis occupied an intermediate
position, representing respectively 69% and 29% of
patients submitted to surgery. These differences clearly
demonstrate the importance of disease extent, currently
considered a biological marker.14
TABLE 2. Clinical Course Related to Demographic and Clinical Characteristics of UC Patients
Remission (N ¼ 1172)
Column % / (Line %)
Chronic Intermittent
(N ¼ 1313)
Column % / (Line %)
Chronic Continuous
(N ¼ 198)
Column % / (Line %) P-value
Age at diagnosis
(media  SD) 40  16 36  15 35  15 P < 0.001a
16 years 4.8 %/(44.7%) 4.7 % / (47.2%) 5.2 % / (8.1%)
17–40 years 48,9 % / (38.6%) 62.1 % / (52.7%) 64.8 % / (8.7%)
>40 years 46.2 % / (53.1%) 33.2 % / (41.0%) 30.1 % / (5.8%) P < 0.001b
Sex
Male/female 44.6/55.4 % /
(44.5 / 43.1 %)
42.2 / 57.8 % /
(47.1 / 50.4 %)
50.0 / 50.0 % /
(8.4 / 6.6%)
P ¼ 0.091b
Clinical presentation
With constitutional symptoms 5.3 % / (31.2%) 7.6 % / (49.7%) 19.3 % / (19.1%)
Without constitutional symptoms 94.7 % / (44.7%) 92.4 % / (48.9%) 80.7 % / (6.4%) P < 0.001b
Extent of disease
Proctitis 26.0 % / (54.0%) 18.9 % / (43.9%) 6.1 % / (2.1%)
Left-sided colitis 51.6 % / (43.5%) 53.4 % / (50.4%) 42.6 % / (6.1%) P < 0.001b
Pancolitis 22.3 % / (36.0%) 27.7 % / (50.1%) 51.3 % / (13.9%)
aKruskal-Wallis nonparametric test.
bChi-square test for independence.
Columns percentages show the proportions of patients with each of 3 clinical courses that fall into different clinical and demographic categories. Lines
percentages show the proportions of patients in each category that turned out to follow each of the 3 clinical courses.
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Despite the negative correlation of smoking with UC
incidence,15 predominantly affecting nonsmokers and for-
mer smokers, there are previous reports showing the inﬂu-
ence of smoking on disease extent and on the clinical
course. In this study less than 8% (7.7) were active smok-
ers, which is signiﬁcantly less than the average 19.7% for
the Portuguese population (National Institute of Statistics,
www.ine.pt). In fact, in contrast to previous reports,16 no
correlation between smoking status and disease extent,
determined as the most proximal level achieved at any
time during disease course, was found. This could reﬂect
previous information that revealed that these differences
were not maintained over a long time period.17
In contrast to recent series from countries tradition-
ally reported as regions of low incidence and milder dis-
ease,18 and similar to data found in Western populations,
14% of the patients needed immunosuppressors and 60%
had taken steroids.
Due to corticoresistance, corticodependence, or need
of immunosuppressors, 34% of patients treated with corti-
costeroids can be considered steroid failures in the long
term. Although different deﬁnitions and time frames were
applied, this percentage was similar to what was found by
others,19 where 38% of patients were considered corticode-
pendent or needing alternative treatments, namely, surgery.
Notwithstanding, one must consider the large propor-
tion of patients (almost 40%) solely treated with salicylates
before discussing therapeutic strategies such as a more
widespread use of immunosuppressors/biologicals or a top-
down approach. This group is noteworthy due to its high
percentage of proctitis.
Although the use of biologics is scarce, 1%, this is
primarily thought to be associated with regulatory reasons.
The study only included patients until December 2006, pre-
cisely the year inﬂiximab was approved for UC by the
EMEA, and therefore the small number of patients treated
with biologicals is due mostly to patients treated off-label
with the drug.
In relation to surgical needs, we found a colectomy
rate (4.5%) lower than most previously reported,20 but
comparable to data from the European multicenter study,21
especially for the southern European centers included
(3.9% at 10 years) and 4 times higher than what was previ-
ously reported for Portugal.4 There is no clear explanation
for this fact, although one could speculate that this is due
to differences in patients’ and in physicians’ perspectives
of disease activity and indications for surgery. As in the
previously mentioned study,21 extent of disease was an im-
portant predictive factor for colectomy, i.e., 0.3% for proc-
titis and 11.2% for pancolitis. Nevertheless, both percen-
tages were lower than that previously reported in studies,
especially from the north of Europe and USA, excluding a
high percentage of extensive colitis as a direct explanation
for the differences in colectomy rates. We also did not ﬁnd
any signiﬁcant differences in the indication for surgery,
with more than 90% of our patients submitted for medical
refractory disease and only a small percentage for cancer/
dysplasia.
FIGURE 2. Disease extent according to the Montreal Classification and disease severity in different intervals of disease dura-
tion. Relative frequency (percentage) for each disease extension category (left axis) and disease severity index (right axis)
classified in 4 disease severity categories defined by the type of treatment administered (adapted from Loftus et al7).
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The disease course of UC was previously described
as remission, chronic intermittent, and continuous course.22
While a signiﬁcant number of patients were in remission at
each year, on a long-term basis the vast majority had addi-
tional symptoms.
In the past the natural history of UC in Portugal
(from a reference university hospital) was reported as mild
or moderate in more than 75% of patients, with 1.1% of
colectomies over a 14.5-year period.4
The overall relapse rate in this study, in which
patients had a median follow-up of 7.8 years, was 57%.
This is remarkably less than what was found by some
authors,20,22,23 but similar to recent reports, particularly
the multicenter European study.10 In this study a cumula-
tive relapse rate of 57% (53%–61%) at 5 years and 67%
(63%–71%) at 10 years were reported. These data indicate
that there is a large proportion of patients with a disease
course characterized by a decrease in symptoms during the
follow-up period, in accordance with the patient’s percep-
tion of their disease as described in the IBSEN study.24 In
that study, 59% of 420 Norwegian patients with UC chose
a disease curve reﬂecting a decrease in symptoms over
time.
In conclusion, this study showed that a large
proportion of UC patients were symptom-free or had
remarkable symptomatic improvement several years after
the diagnosis. Furthermore, a more aggressive phenotype
was detected in extensive colitis and, to a lesser extent, in
younger patients with increased need for steroids and
immunosuppressors.
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